Fig. 5: Enhanced tumor-initiating ability by Trp53 GOF mutation with LOH.
a Strategy of subcutaneous (s.c.) tumor development in NSG mice. b The s.c. tumor size changes in each site injected with 1 × 102 trypsin-dissociated cells of the indicated genotypes are shown as line graphs. The total number of injected sites (n = 14) is indicated in each graph. Each line with closed or open circles, squares, diamonds, or triangles indicates the kinetic tumor size development of an individual tumor. c The total number of developed tumors (y-axis) at the 14 injected sites is shown by red bars. Blue bars indicate number of sites where tumors did not develop. The ratio (%) of tumor development is indicated inside each bar. d The s.c. tumor size changes in each site injected with 5 × 103 mechanically dissociated cells of the indicated genotypes are shown as line graphs. The total number of injected sites (n = 15) is indicated in each graph. Each line with closed or open circles, squares, diamonds, or triangles indicates the kinetic tumor size development of an individual tumor. e The total number of developed tumors (y-axis) at the 15 injected sites is shown. The ratio (%) is indicated inside each bar. f Representative histology photographs of s.c. tumors that developed from 1 × 102 trypsin-dissociated cells. Cell genotypes are indicated in the left. H&E and immunohistochemistry for Ki67, p53, and double fluorescent immunohistochemistry for α-smooth muscle active (αSMA) (green)/E-cadherin (Ecad) (red) are shown. The insets show enlarged images. Bars, 200 µm. Source data are provided as a Source data file.
